Iasophyr (Nitric Oxide)

Nitric oxide released from Iasophyr activates soluble guanylate cyclase in pulmonary smooth‑muscle cells, increasing cyclic GMP levels. The rise in cyclic GMP causes smooth‑muscle relaxation, leading to selective vasodilation of the pulmonary circulation. This mechanism reduces pulmonary vascular resistance without causing significant systemic blood pressure changes.

The dose of Iasophyr is individualized and set by the prescribing clinician based on the patient’s condition, severity of pulmonary hypertension or neonatal distress, and response to therapy. Dosing regimens are adjusted according to clinical monitoring of pulmonary pressures, oxygenation, and safety parameters such as methemoglobin levels.

The safety of Iasophyr (nitric oxide) in pregnancy and lactation has not been definitively established. Current labeling classifies the pregnancy category as unknown, and it should only be used if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a specialist is recommended.

To order Iasophyr, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iasophyr delivers nitric oxide directly to the lungs, offering rapid and selective pulmonary vasodilation. Compared with systemic agents such as phosphodiesterase‑5 inhibitors, it provides targeted action with minimal systemic hypotension. Unlike prostacyclin analogues, it does not require continuous infusion pumps, but it does require specialized inhalation equipment and monitoring.

Store Iasophyr cylinders at ambient temperature, ideally below 25 °C, in a cool, dry location away from direct sunlight. Keep the cylinders upright, protect the regulator from damage, and ensure the gas container remains sealed when not in use. Follow all local regulations for medical gas storage.

Iasophyr is administered via a calibrated inhalation system that delivers a controlled concentration of nitric oxide gas to the patient’s airway. The gas is mixed with the patient’s inspiratory flow, and the delivery device monitors concentration, flow rate, and methemoglobin levels throughout the treatment session.

Serious risks include severe systemic hypotension, rebound pulmonary hypertension after abrupt discontinuation, significant methemoglobinemia (levels >10 %), and rare bleeding complications in patients with coagulopathy. Continuous hemodynamic and methemoglobin monitoring is essential to detect and manage these events promptly.

Iasophyr should be avoided in patients with known hypersensitivity to nitric oxide, severe left‑heart disease, or uncontrolled systemic hypotension. It is also contraindicated in individuals with methemoglobin reductase deficiency or those receiving other potent nitric oxide donors without careful supervision.